Tag:
Abraxane
Latest Headlines
Latest Headlines
Celgene's Abraxane shows promise in pancreatic cancer
A drug that Celgene ($CELG) acquired in its $2.9 billion acquisition of Abraxis BioScience in 2010 is showing promise against the notoriously hard-to-treat p ancreatic cancer.
Celgene keeps biotech spotlight with sanguine Abraxane data in pancreatic cancer
Celgene CEO Bob Hugin is leading a push to rapidly grow the major drugmaker, keeping the company atop lists of go-to partners among biotechs.
Celgene chief Hugin wows J.P. Morgan with blockbuster plans for 2013
Celgene captured the center ring at the J.P. Morgan conference on its opening day Monday. Company CEO Bob Hugin boldly mapped out a 5-year plan to double sales and highlighted upbeat Phase III data on its psoriasis drug apremilast that he believes will set the stage for regulatory approval on both sides of the Atlantic.
Celgene shares jump on Abraxane pancreatic cancer results
The company's cancer drug Abraxane aced a study in pancreatic cancer, boosting patients' survival and forming the foundation for a new FDA approval app.Analysts greeted the data with some impressive sales projections.
Celgene's Abraxane boosts survival in pancreatic cancer
They're popping corks at Celgene ($CELG) headquarters. The company's cancer drug Abraxane aced a study in pancreatic cancer, boosting patients' survival and forming the foundation for a new FDA approval app.
Celgene's Abraxane doubles PFS for melanoma patients in PhIII
Researchers say the data reflect a positive trend for overall survival.
New FDA lung cancer OK for Celgene's Abraxane should boost sales
When Celgene bought out Abraxis two years ago for an eye-popping $2.9 billion, it set out to prove that it could do a better job selling the drug for breast cancer while expanding the drug's use with additional approvals. Today it delivered on part of that promise with an FDA OK on first-line use for advanced or metastatic non-small cell lung cancer.
Celgene's Abraxane delivers in melanoma study
Will Abraxane join the new gang of melanoma fighters?
Celgene's Abraxane delivers in melanoma study
Will Abraxane join the new gang of melanoma fighters? The Celgene ($CELG) drug, a reformulated version of the chemo drug paclitaxel, kept the cancer at bay for longer than the standard chemotherapy, dacarbazine, a new study found.
Celgene gets disappointing Abraxane data
After lifting its earnings projections three times in 2010, Celgene ( $CELG ) is now saying fourth-quarter numbers will miss the mark. But the real disappointment was Abraxane, the drug Celgene bought
